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A B S T R A C T
Purpose: Oxidative stress is recognized as an important factor in progressive myoclonus epilepsy (PME).
Genetic polymorphism of glutathione S-transferases (GSTs), which are involved in both protection from
oxidative damage and detoxiﬁcation, might alter the capacity for protecting tissues from exogenous and
endogenous oxidants. We aimed to assess a possible association between GST polymorphism and PME,
as well as, correlation between GST genotypes and oxidative phenotype in PME patients.
Methods: GSTA1, GSTM1, GSTP1 and GSTT1 genotypes were determined in 26 patients with PME and
66 controls. Byproducts of protein oxidative damage (thiol groups (P-SH) and nitrotyrosine), superoxide
dismutase (SOD) and glutathione peroxidase (GPX) activities were determined.
Results: The frequency of GSTA1, GSTM1 and GSTP1 genotypes was not signiﬁcantly different between
PME patients and controls, while individuals with GSTT1-null genotype were at 5.44-fold higher risk of
PME than carriers of GSTT1-active genotype. Moreover, signiﬁcant risk of PME was obtained in carriers of
both GSTT1-null and GSTM1-null genotypes. Carriers of combined GSTA1- active and GSTT1-null genotype
were at highest, 7.55-fold increased risk of PME. Byproducts of protein damage did not reach statistical
signiﬁcance, while SOD and GPX activities were signiﬁcantly higher in PME patients then in controls.
When stratiﬁed according to GST genotype, P-SH groups were signiﬁcantly lower only in patients with
GSTT1-null genotype in comparison to carriers of active genotype. Only SOD activity was increased in
GSTT1-null when compared to corresponding active genotype.
Conclusions: GSTT1-null genotype might be associated with the increased risk and enhanced
susceptibility to oxidative stress in PME patients.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Progressive myoclonus epilepsies (PMEs) are a group of rare
inherited disorders characterized by the association of epilepsy,
myoclonus and progressive neurological deterioration [1]. Oxida-
tive stress, recognized as one of the predisposing factors in various
neurological disorders, is suggested as an important factor in this
process [2–5]. It has long been known that oxidative stress may
contribute to neuronal hyperexcitability, while antioxidants may
alleviate the progression of PME [2,3,6]. Furthermore, an improve-
ment in the general condition and even reduction of seizures and
myoclonus by antioxidants has been reported in both familial andserved.
M. Ercegovac et al. / Seizure 32 (2015) 30–36 31non-related patients with the same PME syndrome [2,3,6]. Still, the
molecular mechanisms underlying oxidative stress and its role in
progressive myoclonus epilepsy remain elusive.
Oxidative reactions occurring in mitochondria produce oxygen
radicals physiologically in nervous system cells. If a strong
antioxidant defense system is present in the cells, they will be
protected from the damaging effects of reactive oxygen species
[7,8]. Glutathione S-transferases (GSTs) are a superfamily of
enzymes involved in both protection from oxidative damage
and detoxiﬁcation [9]. Furthermore, they play an important role in
metabolizing antiepileptic drugs (AEDs) in liver [10,11]. Namely,
many conventional AEDs undergo metabolism generating active
metabolites, including epoxides, which might have effect on
suppression of epileptic spike, but unfortunately, also in systemic
toxicity via epoxide-induced covalent binding to proteins and
lipids [10,12]. Glutathione S-transferases play an important role in
catalyzing the conjugation of these metabolites to glutathione,
especially in the removal of epoxide metabolites that are generated
during the metabolism of AEDs. Apart from decreasing their
toxicity and facilitating their excretion from the body, it is assumed
that this way GSTs may also affect the response to anticonvulsant
therapy [10].
The most characterized GST classes have been named alpha
(GSTA), mu (GSTM), pi (GSTP) and theta (GSTT). Almost all
members of GST family exhibit genetic polymorphism, resulting
in complete lack or lowering of enzyme activity [9]. Consequent-
ly, individuals lacking certain GST isoenzyme activity may have
altered capacity for protecting tissues from exogenous and
endogenous oxidants, as well as, AEDs [13]. In agreement with
this assumption are the results of Liu and Tsai on enhanced lipid
peroxidation in patients with GSTM1-null genotype and intrac-
table seizure [10]. Another member of GST family, GSTP1, has
been associated with resistance to AEDs treatment. Namely, high
levels of GSTP1 expression in endothelial cells and glial cells/
astrocytes have been shown to correlate to medical intractable
epilepsy [11]. Furthermore, the lack of GSTT1 has been
associated with susceptibility to brain diseases, including
neurodegenerative diseases [14]. Still, the potential role of
genetic polymorphism of GSTs in both risk for development and
resistance to AEDs therapy in patients with PME has to be
established.
This has prompted us to assess a possible association between
GST polymorphism and progressive myoclonus epilepsy. Whether
the null or low-activity GSTA1, GSTM1, GSTP1 and GSTT1genotypes,
alone or in combination, correlate with biomarkers of oxidative
stress in patients with progressive myoclonus epilepsy will be
additionally evaluated.
2. Methods
2.1. Study participants
Genomic DNA was isolated from 26 patients (13 male and
13 female, mean age 20  7.04 years) with progressive myoclonus
epilepsy. Five patients had Unverricht–Lundborg disease, fourteen
Lafora body disease, another ﬁve myoclonic epilepsy with ragged red
ﬁbers and 2 had late infantile neuronal ceroid lipofuscinosis. Patients
were diagnosed based on the clinical history, electrophysiological
ﬁndings and conﬁrmed by molecular genetic studies.
The seizure types in these patients were generalized tonic–
clonic seizures and myoclonus. All patients were on valproic acid
with multiple other antiepileptic drug regimens. Control group
consisted of 66 healthy, non-epileptic subjects, without any drug
treatment, matched for sex, age, ethnicity and geographic origin.
All the participants and/or their parents provided written
informed consent. This study protocol was approved by theInstitutional Review Board, and the research was carried out in
compliance with the Helsinki Declaration (as revised in 2000).
2.2. Molecular genetic studies
Using PCR protocol with betaine, we ampliﬁed promoter region
of the CSTB gene. After separation of ampliﬁed products in 2%
agarose gel along with DNA size standard, we detected a
homozygous expansion of dodecamer repeats in four ULD patients
[15]. Molecular diagnostics of LD, MERRF and NCL patients was
performed by sequencing coding regions of appropriate genes.
2.3. GST genotyping
Genomic DNA was isolated from whole blood using the QIAGEN
QIAmp kit (Qiagen, Inc., Chatsworth, CA). GSTA1 C-69T polymor-
phism was determined by polymerase chain reaction–restriction
fragment length polymorphism (PCR–RFLP) by Ping et al. [16]. The
presence of restriction site resulting in two fragments (481 and
385 bp) indicated mutant allele (T/T) and if C/T polymorphism
incurred, it resulted in one more fragment of 96 bp (Fig. 1a).
GSTM1 genotyping was performed by multiplex PCR [17]. Exon
7 of the CYP1A1 gene was co-ampliﬁed and used as an internal
control. The presence of the GSTM1 active genotype was detected
by the band at 215 bp, since the assay does not distinguish
heterozygous or homozygous wild-type genotypes (Fig. 1b).
GSTP1 Ile105Val polymorphism was analyzed using the PCR–
RFLP method by Harries et al. [18]. The presence of restriction site
resulting in two fragments (91 and 85 bp) indicated mutant allele
(Val/Val), while if Ile/Val polymorphism incurred, it resulted in one
more fragment of 176 bp (Fig. 1c).
GSTT1 genotyping was performed by multiplex PCR [17]. The
assay does not distinguish between heterozygous or homozygous
wild-type genotypes; therefore, the presence of 480 bp bands was
indicative for the GSTT1 active genotype (Fig. 1d).
2.4. Biomarkers of oxidative stress in plasma
The amount of plasma thiol (P-SH) groups was determined
according to the method of Jocelyn and expressed as mmol/g of
proteins (mmol/g prot) [19]. Nitrotyrosine content was measured
by enzyme immunoassay (OxiSelectTM ELISA kits, Cell Biolabs).
Cu, Zn SOD activity in the plasma was measured by the method of
Misra and Fridovich, based on the ability of SOD to inhibit
autooxidation of epinephrine at alkaline pH (pH 10.2) [20]. GPX
activity was determined by the coupled assay procedure of Gunzler
et al. [21].
2.5. Statistical analysis
Statistical analysis was performed using the Statistical Package
for the Social Sciences software (IBM Statistics SPSS, version 20.0).
In descriptive statistics, we summarized all continuous variables
by means  standard deviations (SD). The relative associations
between the studied genotypes and PME risk were evaluated by
multinomial logistic regression to calculate odds ratios (OR) and
corresponding 95% conﬁdence intervals (CI), adjusted according to
age and gender as potential confounding factors. Differences in
investigated biomarkers of oxidative stress were assessed by using x2
test. Statistical evaluation of relationships between biomarkers of
oxidative stress (SH groups, nitrotyrosine, superoxide dismutase and
glutathione peroxidase) and GST genotypes in PME patients was
performed by using the Mann–Whitney rank-sum test (for between-
two-group comparisons) and the Kruskal–Wallis non-parametric test
that compared three unpaired groups. Two-tailed p-values of <0.05
were considered statistically signiﬁcant.
Fig. 1. (a) Agarose gel electrophoretogram. PCR–RFLP products of the GSTA1 gene.
Lanes 4 and 9 represent the GSTA1 CC genotype. Lanes 1, 2, 5, 6 and 10 represent the
GSTA1 CT genotype, while lanes 3, 7 and 8 represent the GSTA1 TT genotype; M, DNA
Q2 marker; N, negative control. (b) Agarose gel electrophoretogram. PCR products
of the GSTM1 gene. Lanes 1, 2, 9, 11 and 12 are patients with the GSTM1 active
genotype and lanes 3 through 8 with lane 10 represent the GSTM- null genotype; M,
DNA Q2 marker; N, negative control. (c) Agarose gel electrophoretogram. PCR–RFLP
products of the GSTP1 gene. Lanes 1 and 2 are wild-type (Ile/Ile), lanes 3, 4 and 5 are
heterozygotes (Ile/Val) and lane 6 is homozygote (Val/Val); M, DNA Q2 marker; N,
negative control. (d) Agarose gel electrophoretogram. PCR products of the GSTT1
gene. Lanes 1, 3, 4 and 5 are patients with the GSTT1 active genotype and lane
2 represents the GSTT1- null genotype; M, DNA Q2 marker; N, negative control.
Table 1
The distribution of GST genotypes in patients with PME and controls.
GST genotype Cases
[n (%)]
Controls
[n (%)]
OR (95%CI) p-Value
GSTA1
CC 11 (42.3) 23 (34.8) 1.0a
CT 14 (53.8) 36 (54.5) 0.81 (0.31–2.09) 0.81
TT 1 (3.8) 7 (10.7) 0.29 (0.03–2.73) 0.29
Low-activity
(CT + TT)
15 (57.7) 43 (65.2) 0.73 (0.29–1.85) 0.50
GSTM1
*1 activeb 12 (46.2) 33 (50) 1.0
*0 nullc 14 (53.8) 33 (50) 1.16 (0.47–2.89) 0.74
GSTP1
Ile/Ile 13 (50) 29 (43.9) 1.0
Ile/Val 9 (34.6) 29 (43.9) 0.69 (0.25–1.86) 0.46
Val/Val 4 (15.4) 8 (12.1) 1.15 (0.29–4.37) 0.87
Low-activity
(Ile/Val + Val/Val)
13 (50) 37(66) 0.78 (0.31–1.95) 0.60
GSTT1
*1 active 10 (38.5) 51 (77.3) 1.0
*0 null 16 (61.5) 15 (22.7) 5.44 (2.04–14.46) 0.001
OR, crude odds ratio; CI, conﬁdence interval.
a Reference category.
b Active (present) if at least one active allele is present.
c Null (inactive) if no active alleles present.
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differences between multiple groups, if it was necessary.
3. Results
3.1. GST genotype and PME risk
The distribution of GST genotypes in patients with progressive
myoclonus epilepsy and controls is presented in Table 1.
The frequency of GSTA1, GSTM1 and GSTP1 genotypes was not
signiﬁcantly different in PME patients in comparison to controls.
Although it seems that in case of GSTA1 polymorphism, low-
activity (T) allele might have some effect on decreasing the risk for
PME, statistical signiﬁcance was not reached. Signiﬁcant associa-
tion between the GST genotype and risk of PME was found only for
the GSTT1 genotype. Namely, individuals with GSTT1-null genotypewere at 5.44-fold higher risk of PME (OR = 5.44, 95% CI = 2.04–
14.46, p = 0.001) than individuals carrying the GSTT1-active
genotype.
When GST genotypes were analyzed in combination (Table 2),
the signiﬁcant risk of PME was obtained in subjects who carried
both GSTT1-null and GSTM1-null genotypes (OR = 6.28, 95%
CI = 1.70–23.13, p = 0.006), which was preserved after Bonferroni
correction. Combination of GSTT1-null with the GSTP1-low-activity
genotype was also found to be signiﬁcant (OR = 4.28, 95%
CI = 1.17–15.57, p = 0.027), however the risk for PME was lower
than in case of individual GSTT1-null genotype. Furthermore, after
Bonferroni correction statistical signiﬁcance was nulliﬁed. Inter-
estingly, when GSTT1-null genotype was combined with both active
and low-activity GSTA1 genotype, 7.55 and 5.03 fold higher risk for
PME was obtained (OR = 7.55, 95% CI = 1.49–38.02, p = 0.014 and
OR = 5.03, 95% CI = 1.06–23.81, p = 0.041, respectively). Since in
case of combined active GSTA1 and GSTT1-null genotype even after
Bonferroni correction statistical signiﬁcance was preserved, it
practically means that carriers of combined active GSTA1 and
GSTT1-null genotype are at highest risk for development of
progressive myoclonus epilepsy. On the other hand, similarly to
combined GSTT1-null and GSTP1-low-activity genotype, the risk for
PME in carriers of combined GSTA1 low-activity and GSTT1-null
genotype was lower than in case of individual GSTT1-null genotype.
3.2. Association between GST genotype and biomarkers of oxidative
stress
Table 3 summarizes the data on the degree of oxidative and
nitrosative damage to proteins, as well as, major antioxidant
enzyme activities in patients with PME. Although plasma protein
thiol groups content was lower and nitrotyrosine was found to be
higher in patients with PME in comparison to healthy controls, this
change in byproducts of protein damage did not reach statistical
signiﬁcance. However, the activities of antioxidant enzymes,
superoxide dismutase and glutathione peroxidase, were found
to be statistically signiﬁcantly higher in PME patients when
compared to controls (p = 0.003 and 0.005, respectively; Table 3).
Results obtained when biomarkers of oxidative stress were
stratiﬁed according to GST genotypes are presented in Table 4.
Table 2
Combined effects of GST genotypes in relation to the risk of PME.
GSTT1 GSTA1
Activea Nullb Active Low activity
GSTA1
Active – –
Ca/Co 3/17 8/6
OR(95%CI) 1.0 7.55 (1.49–38.02)
p-Value 0.014
Low activity – –
Ca/Co 7/34 8/9
OR(95%CI) 1.16 (0.26–5.08) 5.03 (1.06–23.81)
p-Value 0.837 0.041
GSTM1
Active
Ca/Co 7/24 5/9 3/10 9/23
OR(95%CI) 1.0 1.90 (0.47–7.57) 1.0 1.30 (0.29–5.86)
p-Value 0.360 0.769
Null
Ca/Co 3/27 11/6 8/13 6/20
OR(95%CI) 0.38 (0.08–1.64) 6.28 (1.70–23.13) 2.05 (0.43–9.78) 1.0 (0.20–4.85)
p-Value 0.190 0.006 0.367 1
GSTP1
Active
Ca/Co 7/21 6/8 4/10 9/19
OR(95%CI) 1.0 2.25 (0.57–8.75) 1.0 1.18 (0.29–4.82)
p-Value 0.243 0.814
Low activity
Ca/Co 3/30 10/7 7/13 6/24
OR(95%CI) 0.30 (0.07–1.29) 4.28 (1.17–15.57) 1.34 (0.30–5.91) 0.62 (0.14–2.70)
p-Value 0.107 0.027 0.694 0.625
Ca/Co, cases/controls. OR, crude odds ratio. CI, conﬁdence interval. Signiﬁcance at p  0.025. GSTA1 active, CC; GSTA1 low activity, CT+TT; GSTP1 active, Ile/Ile; GSTP1 low-activity,
Ile/Val+Val/Val.
a Active (present) if at least one active allele is present.
b Null (inactive) if no active alleles present.
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patients with GSTM1-null, as well as, GSTT1-null genotypes in
comparison to corresponding active genotypes, however statisti-
call signiﬁcance was reached only in patients with GSTT1-null
genotype (p = 0.042). After Bonferroni correction the observed
statistical signiﬁcance was nulliﬁed. Although nitrotyrosine, a
reliable marker of nitrosative damage of proteins, was found to be
higher in patients with the GSTM1-null genotype in comparison to
GSTM1 active genotype, this increase did not reach statistical
signiﬁcance (p = 0.089).
Regarding antioxidant enzyme activities, only SOD, when
stratiﬁed according to GSTT1 polymorphisms, showed change in
activity (p = 0.055). Namely, SOD activity was found to be
increased in GSTT1-null when compared to corresponding active
genotype, however statistically unsigniﬁcant.Table 3
Biomarkers of oxidative stress in patients with PME and controls.
Biomarker Patients with PME Controls p-Value
SH-groups (mmol/g prot) 6.78  1.56a 8.22  1.79 0.175
% 82.5 100
Nitrotyrosine (nmol/L) 42.69  9.29 34.40  19.44 0.243
% 124.09 100
SOD (U  103/L) 45.81  10.10 33.39  10.75 0.003
% 137.2 100
GPX (U/L) 409.91  148.02 301.37  38.02 0.005
% 136 100
SH-groups—protein thiol groups. SOD—superoxide dismutase. GPX—glutathione
peroxidase.
a Values are presented as mean  standard deviation.4. Discussion
Based on the premise that oxidative stress is associated with
pathogenesis and progression of progressive myoclonus epilepsy
[2–5], we speculated that variations in antioxidant and detoxifying
activities of glutathione S-transferases might modulate individual
tendency toward PME development. Among four GST polymor-
phisms analyzed in this study, only the GSTT1-null genotype has
shown a signiﬁcant association with PME that was even more
pronounced if GSTM1- null genotype was also present. When
GSTT1-null genotype is associated with remaining two GST
genotypes, GSTA1 and GSTP1, the risk for PME development is
shown to be increased in carriers of both active and low-activity
genotypes. To our knowledge, this is the ﬁrst investigation that
addressed the association of common GST polymorphisms and
PME.
As suggested, susceptibility to progressive myoclonus epilepsy
might depend on expression proﬁles of enzymes involved in both
protection from oxidative damage and detoxiﬁcation [9–11]. In-
deed, individuals lacking certain GST isoenzyme activity may have
altered capacity for protecting tissues from exogenous and
endogenous oxidants [13]. Polymorphism of GSTT1, the only
GST polymorphism which might be independently associated to
PME risk, has so far been mostly related to risk of various human
cancers [14]. Interestingly, although not conﬁrmed in all the
studies, the lack of GSTT1 is associated with increased susceptibil-
ity to brain tumors, such as astrocytoma, meningeoma, oligoden-
droglioma, but also neurodegenerative diseases [22–24]. Namely,
the lack of GSTT1 activity was associated with an increased risk of
Alzheimer’s disease, Parkinson’s disease and motor neuron disease
Table 4
Biomarkers of oxidative stress in relation to GST genotypes in patients with PME.
GST genotype SH-groups (mmol/g prot) Nitrotyrosine (nmol/L) SOD (U  103/L) GPX (U/L)
GSTA1
Active 6.21  0.82a 41.12  6.56 43.29  7.22 412.24  118.12
Low-activity 7.45  0.87 42.34  4.39 39.63  6.71 407.69  113.56
p-Value 0.084 0.316 0.115 0.591
GSTM1
*1 activeb 7.26  1.02 37.74  4.23 43.45  6.35 429.89  129.32
*0 nullc 6.04  0.77 43.58  7.18 48.08  7.03 380.39  109.05
p-Value 0.057 0.089 0.427 0.100
GSTP1
Active 5.93  0.64 40.52  6.62 47.12  8.96 390.86  102.78
Low-activity 7.05  0.78 41.30  5.18 43.74  7.12 409.09  111.06
p-Value 0.109 0.496 0.254 0.328
GSTT1
*1 active 7.88  0.41 40.21  6.29 40.67  4.93 414.47  130.53
*0 null 6.13  0.77 42.77  8.13 49.32  6.44 375.45  102.84
p-Value 0.042 0.118 0.055 0.280
SH-groups—protein thiol groups. SOD—superoxide dismutase. GPX—glutathione peroxidase. Signiﬁcance at p  0.025. GSTA1 active, CC; GSTA1 low activity, CT+TT; GSTP1
active, Ile/Ile; GSTP1 low-activity, Ile/Val + Val/Val.
a Values are presented as mean  standard deviation.
b Active (present) if at least one active allele is present.
c Null (inactive) if no active alleles present.
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individuals unexposed to neurotoxins, it might be hypothesized
that the metabolism of neurotoxins or other endogenous
substances can vary in different GSTT1 backgrounds, affecting
the risk of diseases in the central nervous system.
Another GST polymorphism, GSTM1-null, was shown to increase
risk for PME development in our study, however only when
combined with GSTT1-null genotype. Glutathione S-transferase M1
has so far been associated with enhanced oxidative damage to
lipids and poor response to antiepileptic drugs in patients with
epilepsy [10]. However, Shang et al. have reported no signiﬁcant
association between GSTM expression in brains of patients with
intractable epilepsy with failure to response to AEDs [11]. In
general, GSTM1-null and GSTM1-null/GSTT1-null genotypes have so
far, in patients with any type of epilepsy, been mostly investigated
as risk factors for carbamazepine (CBZ) and valproic acid (VPA)-
induced hepatotoxicity [25,26].
Alpha class of GSTs, which interestingly affects the risk for PME
development when in combination with GSTT1-null genotype, in
carriers of both active and low-activity GSTA1 genotypes, has been
evaluated only in pregnant woman with epilepsy [27] and in
patients with medically intractable seizures, where its expression
was not found in brain [11]. This result is rather unusual, since
alpha class GSTs are widely expressed in most tissues, including
brain [28]. Dieckhaus et al. have investigated the role of GSTA in
terms of detoxiﬁcation of 2-phenylpropenal, a reactive felbamate
metabolite which was considered effective therapy for refractory
epilepsy, but limited due to the associated reports of hepatotoxici-
ty and aplastic anemia [29]. However, no signiﬁcant association
was found. Taken together, the only possible explanation for the
effect on the risk for developing PME might be in the potential role
of GSTA1 in bioactivation of certain neurotoxic compounds.
Namely, although GSTs constitute an important part of the cellular
detoxiﬁcation system through the conjugation of glutathione
(GSH) with genotoxic substrates, they are also responsible for the
bioactivation of several drugs, for example, TLK-286, brostallicin
and thiopurines such as Azathioprine, which has been used in
organ transplantation and in the treatment of autoimmune
diseases and cancer for decades [30].
Situation is rather similar with GSTP1 polymorphism, which
also affects the risk for PME development only in combination with
GSTT1-null genotype. Still, expression of GSTP1 was found to be
signiﬁcantly higher in brain specimens from patients withepilepsy, than in controls [11]. Furthermore, Deng et al. have
found that the change in expression of GSTP in peripheral blood
shows the same pattern as that in brain tissues, suggesting GSTP
might contribute to drug resistance in epilepsy, suggesting that the
GSTP over-expression in peripheral blood could be used as a
marker for resistance to anti-epileptic agents [31].
The assumption that lacking or low-activity GST gene variants
might contribute to increased susceptibility to oxidative stress in
patients with PME has been partially conﬁrmed in the next phase
of this investigation, in which the inﬂuence of polymorphic GSTA1,
GSTM1, GSTP1 and GSTT1 genes was analyzed with respect to
oxidative phenotype. Namely, all products of analyzed GST genes
possess both glutathione conjugating and antioxidant enzymatic
activity [9]. However, according to the results presented in this
study, the level of protection against oxidative stress in progressive
myoclonus epilepsy might be inﬂuenced by common GST
polymorphisms which determine the quantity and/or activity of
GST protein ‘echelons’ that act upon accumulated harmful
compounds.
Oxidative damage to proteins is one of the major mechanisms
underlying neuronal cell damage [32]. We demonstrated that the
concentration of protein sulfhydryl groups in plasma, which are
important chain breaking antioxidant [32] is reduced in patients
with PME. Decreased P-SH levels may be a consequence of
enhanced free radicals production in epileptic seizure, since
sulfhydryl groups of plasma proteins have been suggested to be a
‘‘sacriﬁcial’’ antioxidant in plasma and extravascular spaces
[33]. Results on decreased P-SH content in patients with PME
are in agreement with our previous ﬁndings obtained in patients
with partial cryptogenic and generalized idiopathic epileptic
seizures [34]. Further analysis, based on association to different
GST genotypes, showed that decrease in P-SH levels was the most
obvious in patients carrying either GSTM1-null or GSTT1-null
genotype. It means that individual GST polymorphisms inﬂuence
vulnerability to protein oxidation, with GSTM1-null or GSTT1-null
gene variants having the most pronounced effect in patients with
PME. This might be explained by the fact that individuals with the
GSTM1-null/GSTT1-null genotype have lower total antioxidant
capacity than those with both active genotypes, as suggested by
Tang et al. [35]. Nitrotyrosine, a reliable marker of nitrosative
damage to proteins, was found to be higher in patients with
progressive myoclonus epilepsy. Although the association be-
tween GST null or low-activity gene variants and plasma
M. Ercegovac et al. / Seizure 32 (2015) 30–36 35nitrotyrosine level in PME patients was relatively mild, our
ﬁndings suggest that their antioxidant activities, especially GSTM1
polymorphism, at least partially affect the level of nitrosative
damage.
The question that arises is how antioxidant enzymes contribute
to oxidative phenotype in patients with PME. Extracellular SOD
represents a major defense system against superoxide, being also a
target for oxidative damage [36]. Hurd et al. have reported an
increase in serum extracellular SOD activity in the progressive
myoclonus epilepsies [37]. Similar ﬁndings were reported by Ben-
Menachem et al. who found increased plasma SOD activity, but
decreased erythrocyte SOD activity in patients with PME [3]. Our
results on signiﬁcant increase in plasma SOD activity in patients
with PME are in agreement with these ﬁndings. Furthermore,
when SOD activity was analyzed in relation to GST genotypes, the
association was found only in case of GSTT1 polymorphisms.
Therefore, it seems that individuals who lack GSTT1 enzyme
activity have higher SOD activity as an adoptive phenomenon
compensating increased oxidative stress, that implies possible
genetic predisposition to worse oxidative phenotype. Contrary to
these ﬁndings, Wu et al. have shown that in patients with
myoclonus epilepsy with ragged-red ﬁbers syndrome levels of
mitochondrial SOD were increased, while extracellular SOD
remained unchained [38].
The data on another antioxidant major enzyme, GPX, in patients
with PME are rather limited. Extracellular GPX is presumed to
work as a part of a traditional glutathione cycle [39]. The tripeptide
glutathione is involved in disposal of peroxides by brain cells and
in protection against reactive oxygen species, while its content in
brain cells depends strongly on the availability of precursors for
glutathione [40]. The pattern of changes observed in our study for
plasma GPX activity in patients with PME resembles that of SOD.
Namely, we have shown a signiﬁcant increase in plasma GPX
activity in patients with PME, although it could not be associated to
any of analyzed GST genotypes. Our ﬁndings are in contrast to Ben-
Menachem et al. who have found no signiﬁcant change in GPX
activity in patients with Unverricht–Lundborg and Lafora body
disease in comparison to healthy individuals [3]. In that line, Wu
et al. also found no signiﬁcant change in GPX activity in cultured
cells of patients with myoclonus epilepsy with ragged-red ﬁbers
syndrome [38].
Based on the results of this investigation it may be concluded
that presence of GSTT1-null genotype might be associated with the
increased risk of PME development and enhanced susceptibility to
oxidative stress in these patients. The effect is most pronounced if
GSTT1-null and GSTM1-null genotypes are present in combination
in patients with PME. In addition to risk, our results may have
implications in new approaches to the antioxidant therapy in
patients with PME. Namely, taken together, these results suggest a
possibility for GST genotype based stratiﬁcation of patients with
PME which could improve the attempts toward the individualiza-
tion of the antioxidant treatment. Since susceptibility to oxidative
damage differs with respect to GST genotype, it seems reasonable
to assume that individuals’ GST ‘‘genetic proﬁle’’, in addition to
plausible oxidative stress biomarkers, should be also considered
in optimization of form, dose and time course of antioxidant
treatment. So far, high doses of N-acetylcysteine (NAC), a
glutathione precursor, have been shown to markedly improve
and stabilize neurological condition in patients with Unverricht–
Lundborg disease [2,3], while the effect was doubtful in case of
Lafora body disease [3]. Furthermore, Edwards et al. have shown
that increase in glutathione levels during treatment with NAC was
followed by an improvement in seizures, but not in myoclonus or
ataxia in patients with PME [6]. Hachiya et al. also suggested usage
of antioxidant agents in treatment of neuronal ceroid-lipofusci-
noses [41].Certain limitations might be considered in our study. The case–
control design was used for estimating of associations between
GST genotypes and PME development and therefore the selection
bias might inﬂuence the results. Due to a limited number of
patients with different types of PME, it was not possible to
evaluate association between speciﬁc types of progressive
myoclonus epilepsy and biomarkers of oxidative stress. Further-
more, evaluation of polymorphic expression of GSTs in terms of
speciﬁc PME outcome might provide information that could affect
the treatment of these patients, however, on much larger study
population. A meta-analysis of previously published studies
might contribute to interpretation of ﬁndings in this study,
however no other studies of association between GSTA1, GSTM1,
GSTP1 and GSTT1 polymorphisms and PME exist. Still, although
the sample size is rather small, this study may offer some essential
information that could be the base for future longitudinal
research.
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